Skip to content

The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection

The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04664049
Enrollment
51000
Registered
2020-12-11
Start date
2020-12-23
Completion date
2022-12-31
Last updated
2021-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid 19, SARS-CoV-2

Keywords

NRICM101, Covid 19, SARS-CoV-2

Brief summary

Traditional Chinese medicine is regarded as a dietary supplement in many countries around the world. Dietary supplement, NRICM101, has been available for people who diagnosed, suspected or prevented for coronavirus disease 2019 (COVID-19) in September 2020. It is expected to help people not to progress to severe illness, and reduce lung damage and mortality. The investigators gather the effects of people who taking NRICM101 using the Real-World Big Data Study and the network feedback information collection model. This study can be used as a reference for global prevention and control of coronavirus disease 2019 (COVID-19).

Detailed description

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is raging around the world. Because of its strong spread, variability, survivability, and invisibility, the number of infected people rise rapidly. On March 11, 2020, the WHO officially declared COVID-19 as a pandemic disease. As of October 3, 2020, the number of confirmed cases has exceeded 34 million, and the cumulative deaths have exceeded 1 million. There are still no drugs to treatment the coronavirus disease 2019 (COVID-19). Due to the mutation of virus rapidly, vaccine development cannot be completed in a short period of time. At the beginning of the infection outbreak, the governments of China and South Korea, adopted a cooperative of Chinese and Western medicine to treatment the coronavirus disease 2019 (COVID-19). In addition to the reported good clinical effects, Chinese medicine prescriptions have included in diagnosis and treatment guideline of these two countries. Traditional Chinese medicine is regarded as a dietary supplement in many countries around the world. Dietary supplement, NRICM101, has been available for people who diagnosed, suspected or prevented for coronavirus disease 2019 (COVID-19) in September 2020. It is expected to help people not to progress to severe illness, and reduce lung damage and mortality. The investigators gather the effects of people who taking NRICM101 using the Real-World Big Data Study and the network feedback information collection model. This study can be used as a reference for global prevention and control of coronavirus disease 2019 (COVID-19).

Interventions

DIETARY_SUPPLEMENTNRICM101

Direction: Take 1 sachet 2-4 times daily directly or with 400cc water before or between meals Indication: Externally contracted seasonal epidemic Function: Relieving Exterior and Facilitating Lung, clear heat of lung, Wide chest and resolve phlegm

Sponsors

National Research Institute of Chinese Medicine, Ministry of Health and Welfare
Lead SponsorOTHER_GOV

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Subjects who confirmed, suspected or prevented infected of COVID 19 disease and take dietary supplement NRICM101

Exclusion criteria

* Those who refuse to participate in observational research.

Design outcomes

Primary

MeasureTime frameDescription
negative of COVID-19 test1 day to 2 monthsreceive COVID 19 test and the result is negative
free of COVID 19 disease symptoms and signs1 day to 2 monthsfree of COVID 19 disease symptoms and signs after took NRICM101

Countries

Taiwan

Contacts

Primary ContactYi-Chang Su, MD, PhD
sychang@nricm.edu.tw886-2-2820-1999
Backup ContactChien-Jung Lin, MD, PhD
linchienjung@yahoo.com886-2-8792-3311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026